ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation Therapy

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

A prospective phase 2 trial evaluated the use of de-escalation therapy for patients with p16-positive squamous cell carcinoma.

The role of multimodal approaches such as FDG-PET imaging may require further investigation in patients with human papillomavirus–positive oropharyngeal cancer, according to Samuel Regan, MD.